Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moderate to severe atopic dermatitis

Trial Profile

A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moderate to severe atopic dermatitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2018

At a glance

  • Drugs MOR 106 (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms IGUANA
  • Sponsors Galapagos NV
  • Most Recent Events

    • 19 Dec 2018 Planned number of patients changed from 180 to 240.
    • 19 Jul 2018 According to a MorphoSys media release, MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner,Upon the signing of the agreement, all future research, development, manufacturing and commercialization costs for MOR106 will be borne by Novartis.
    • 01 May 2018 Status changed from planning to recruiting, according to a MorphoSys media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top